Literature DB >> 31186867

Management of nonalcoholic steatohepatitis: Pharmacotherapy.

Vlad Ratziu1.   

Abstract

Entities:  

Year:  2012        PMID: 31186867      PMCID: PMC6499280          DOI: 10.1002/cld.74

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN: 2046-2484


× No keyword cloud information.
  10 in total

1.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Authors:  Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

2.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Gastroenterology       Date:  2012-05-15       Impact factor: 22.682

3.  High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.

Authors:  Ulrich F H Leuschner; Birgit Lindenthal; Günter Herrmann; Joachim C Arnold; Martin Rössle; Hans-Jörg Cordes; Stefan Zeuzem; Jasper Hein; Thomas Berg
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

4.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

5.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

6.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Authors:  Renata Belfort; Stephen A Harrison; Kenneth Brown; Celia Darland; Joan Finch; Jean Hardies; Bogdan Balas; Amalia Gastaldelli; Fermin Tio; Joseph Pulcini; Rachele Berria; Jennie Z Ma; Sunil Dwivedi; Russell Havranek; Chris Fincke; Ralph DeFronzo; George A Bannayan; Steven Schenker; Kenneth Cusi
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

Review 7.  Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.

Authors:  Vlad Ratziu; Stephen Caldwell; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2010-12       Impact factor: 17.425

8.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Authors:  Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

9.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.

Authors:  Stephen A Harrison; Will Fecht; Elizabeth M Brunt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

10.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.

Authors:  Valerio Nobili; Melania Manco; Rita Devito; Vincenzo Di Ciommo; Donatella Comparcola; Maria Rita Sartorelli; Fiorella Piemonte; Matilde Marcellini; Paul Angulo
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.